Report: Defibrillators may be a tough sell for Boston Scientific

Boston Scientific Corp. may face a tough time selling its defibrillators as doctors shun them in the wake of several recalls of the devices, Bloomberg news reported this morning.

The company was mentioned in a report by analyst Robert Faulkner of JMP Securities in New York, which said that defibrillator sales plunged 12 percent to $1.37 billion in the second quarter. The cause: doctor and patient worries after 300,000 defibrillator implants were recalled starting last February.

Boston Scientific has 500 defibrillator-related lawsuits pending and saw sales of the devices drop by 20 percent last quarter, the Bloomberg report said.
(By Keith Reed, Globe staff)